(Q43473600)

23 November 2017

title

Effects of different meal compositions and fasted state on the oral bioavailability of etravirine (English)

1 reference

23 November 2017

1 reference

2

Marta Boffito

1 reference

23 November 2017

author name string

Monika Schöller-Gyüre

1

1 reference

23 November 2017

Anton L Pozniak

3

1 reference

23 November 2017

Ruud Leemans

4

1 reference

23 November 2017

Thomas N Kakuda

5

1 reference

23 November 2017

Brian Woodfall

6

1 reference

23 November 2017

Veerle Vyncke

7

1 reference

23 November 2017

Monika Peeters

8

1 reference

23 November 2017

Kati Vandermeulen

9

1 reference

23 November 2017

Richard M W Hoetelmans

10

1 reference

23 November 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

23 November 2017

1 reference

23 November 2017

volume

28

1 reference

23 November 2017

issue

10

1 reference

23 November 2017

page(s)

1215-1222

1 reference

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1215

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1215

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1215

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1215

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1215

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1215

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1215

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1215

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1215

Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1215

Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1215

Effects of food on drug absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1215

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.10.1215

1 reference

23 November 2017

1 reference